# Vera Therapeutics (VERA) — News

VERA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/vera/news

## Recent headlines

- [Moody's Ratings affirms WePA's BA3 CFR, changes outlook to stable from positive](https://www.ainvest.com/news/moody-ratings-affirms-wepa-ba3-cfr-outlook-stable-positive-2610) — AInvest Wire, Oct 13, 2026
- [Mohamed Aiman Kamal El Din Mohamed Abdul Khaliq Korra sells 34.2 mln shares in Korra Holding for EGP 205.3 mln - EGX](https://www.ainvest.com/news/mohamed-aiman-kamal-el-din-mohamed-abdul-khaliq-korra-sells-34-2-mln-shares-korra-holding-egp-205-3-mln-egx-2610) — AInvest Wire, Oct 13, 2026
  Mohamed Aiman Kamal El Din Mohamed Abdul Khaliq Korra has sold 34.2 million shares in Korra Holding (KORA) for a total value of EGP 205.3 million, according to recent data from the Egyptian Exchange . The transaction reflects significant activity in the stock, which has seen a recent decline in…
- [Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(C)(4)](https://www.ainvest.com/news/vera-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-4-2610) — AInvest Wire, Oct 2, 2026
- [Vera Therapeutics shares up 1.5% after kidney disease drug meets goals in confirmatory trial](https://www.ainvest.com/news/vera-therapeutics-shares-1-5-kidney-disease-drug-meets-goals-confirmatory-trial-2609) — AInvest Wire, Sep 15, 2026
  Vera Therapeutics Inc. (NASDAQ: VERA) reported that its investigational drug for the treatment of IgA nephropathy, a progressive kidney disease, met its primary and key secondary endpoints in a confirmatory Phase 3 clinical trial [1]. The drug, currently in late-stage development, demonstrated…
- [Vera Therapeutics shares jump 14% after Trutakna update](https://www.ainvest.com/news/vera-therapeutics-shares-jump-14-trutakna-update-2609) — AInvest Wire, Sep 15, 2026
  Vera Therapeutics, Inc. (VERA) shares rose approximately 14% in early trading on September 15, 2026, following an update regarding its Trutakna™ development program. The increase reflects investor optimism about the company’s progress in advancing its therapeutic pipeline. Year-to-date, VERA has…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).